Skip to main content
Erschienen in: BMC Psychiatry 1/2023

Open Access 01.12.2023 | Editorial

First episode psychosis and beyond: much progress made but much more needed

verfasst von: Shuichi Suetani, Wei Wang

Erschienen in: BMC Psychiatry | Ausgabe 1/2023

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

First episode psychosis remains one of the most critical research areas in psychiatry. Much progress has been made, but more progress is required to translate the ideas and promises into reality. In this Editorial, we provide the context and invite contributions for our BMC Psychiatry Collection on First Episode Psychosis.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In the 1980s, a 10-bed clinical research unit for people with first episode psychosis (FEP) was established in Melbourne, Australia, with two main tasks [1]. First, to reduce and prevent the harm that people with FEP were exposed to by separating them from people with more pervasive mental disorders and the messages and treatments that were draining hope and optimism. Second, to develop and evaluate psychosocial interventions for patients and their families that were relevant and appropriate for the stage of illness and psychosocial development. The intriguing idea of a critical period for psychotic disorders – perhaps the first five years after the onset of FEP – having a disproportionate long-term impact was proposed [2]. Australia led the innovation by establishing EPPIC (Early Psychosis Prevention and Intervention Centre), and other countries soon followed with similar programs. Much like another Australian innovation, Lithium [3], the FEP paradigm (“a stitch in time…”) changed how we conceptualize and practice psychiatry. Key concepts such as the duration of untreated psychosis [4], prodromal symptoms [5], and ultra-high risk mental state [6] became well embedded within our lexicon. The International Early Psychosis Association was established in the early 1990s, and Early Intervention in Psychiatry journal was published in the late 2000s [1].
Despite its promises and intuitive logic behind the idea, the FEP paradigm also attracted much criticism. In 2011, Professor Allen Frances, the Chair of the task force overseeing the development and revision of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders, expressed his concern that the FEP paradigm was prematurely being implemented into clinical practice without sufficient foundations. Namely, he argued (i) accurate diagnosis, (ii) interventions with proven efficacy and (iii) proven safety had not yet been established adequately for the FEP paradigm [7]. More than a decade has passed but the detection and diagnosis of FEP remain challenging due to its fluid, heterogeneous and often vague symptomatology [8]. The stigma associated with mental illness, particularly psychotic disorders, persists, making timely access and diagnosis difficult [9]. Further, only around one in four people presenting with a high clinical risk for psychosis actually transition into psychosis within three years [10]. To this day, there remain no approved interventions that have been shown to improve the long-term course of psychotic disorders, and specialized integrated early intervention services do not substantially reduce the risk of having a relapse compared to standard care [11]. More recently, this high psychosis risk cum psychotic disorder transition concept has been questioned. Van Os and Guloksuz [12] argue that it is neither clinically useful nor scientifically valid to reduce the transdiagnostic expression of psychosis in early states of multidimensional psychopathology to the binary concepts of risk and transition. Accordingly, some groups, including Orygen in Australia, are moving towards widening the “at risk mental state” model beyond psychotic disorders to take a more transdiagnostic approach [13]. Heated debates around the benefits of the FEP paradigm in the real world persist even (or perhaps especially) in Australia, where Professor Patrick McGorry was awarded the Australian of the Year in 2010 for his work in youth mental health [1417]. Patel captured one sentiment among the clinicians at the coal face in the response to an article titled Why do psychiatrists doubt the value of early intervention? The power of illusion by McGorry and Mei [17]: “Clinician’s reality may reflect the experience of seeing the long-term outcomes of schizophrenia unchanged by [early intervention] whilst the authors reality reflects the experience of shorter-term outcomes for a much broader and heterogeneous psychosis group. The progressive underfunding of services for the former during a period of rapid growth in services for an even more ill-defined ‘youth mental health’ group championed by McGorry further diminishes his relevance of his views for the ‘disillusioned’ clinician” [18].
Forty years on, some critical questions remain unanswered in the field of FEP research. First, what are the causes of FEP? Is the onset of FEP one of the earliest signs of a pervasive brain disease, or do cultural, social and environmental factors contribute to FEP? Related to this, is the onset of FEP really the beginning of a critical period for intervention [2]? If so, how long does this critical period last and what more can we do to reduce the duration of untreated psychosis? Second, what are the consequences of FEP? What are the different phenotypes and endotypes of FEP? What are the long-term functional and personal impacts of FEP beyond clinical prognosis? Can we “cure” FEP? If not, why not? Finally, and perhaps most importantly, how do we translate the short-term efficacy seen in clinical trials into sustained effectiveness for our patients and their families in real life? Is there more we can do at the individual level? What more should we be doing at the societal and policy levels? The truth is, despite much progress in the field, the mortality gap among people with severe mental disorders has widened [19], and the recovery rate among people with psychotic disorders remains unchanged [20].
The FEP paradigm has given us a unique and valuable foundation to explore and examine mental disorders in general, psychotic disorders in particular. We have come a long way, but we are not there yet. We hope this Collection will provide another step towards a better future for people experiencing FEP and their families. We progress by testing ideas and rejecting ideologies. We must continue to seek effective and safe pharmacological, psychosocial and other interventions that will reduce and resolve the sufferings associated with FEP.

Acknowledgements

Nil.

Declarations

Not applicable.
Not applicable.

Competing interests

Nil.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Birchwood M, Macmillan F. Early intervention in schizophrenia. Aust N Z J Psychiatry. 1993;27(3):374–8.CrossRefPubMed Birchwood M, Macmillan F. Early intervention in schizophrenia. Aust N Z J Psychiatry. 1993;27(3):374–8.CrossRefPubMed
3.
Zurück zum Zitat Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–52.CrossRefPubMed Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–52.CrossRefPubMed
4.
Zurück zum Zitat Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149(9):1183–8.CrossRefPubMed Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149(9):1183–8.CrossRefPubMed
5.
Zurück zum Zitat Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587–99.CrossRefPubMed Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587–99.CrossRefPubMed
6.
Zurück zum Zitat Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57–66.CrossRefPubMed Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57–66.CrossRefPubMed
7.
Zurück zum Zitat Frances A. Psychosis risk syndrome–far too risky. Aust N Z J Psychiatry. 2011;45(10):803–4.CrossRefPubMed Frances A. Psychosis risk syndrome–far too risky. Aust N Z J Psychiatry. 2011;45(10):803–4.CrossRefPubMed
8.
Zurück zum Zitat Griffiths SL, Leighton SP, Mallikarjun PK, Blake G, Everard L, Jones PB, Fowler D, Hodgekins J, Amos T, Freemantle N, et al. Structure and stability of symptoms in first episode psychosis: a longitudinal network approach. Transl Psychiatry. 2021;11(1):567.CrossRefPubMedPubMedCentral Griffiths SL, Leighton SP, Mallikarjun PK, Blake G, Everard L, Jones PB, Fowler D, Hodgekins J, Amos T, Freemantle N, et al. Structure and stability of symptoms in first episode psychosis: a longitudinal network approach. Transl Psychiatry. 2021;11(1):567.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kular A, Perry BI, Brown L, Gajwani R, Jasini R, Islam Z, Birchwood M, Singh SP. Stigma and access to care in first-episode psychosis. Early Interv Psychiatry. 2019;13(5):1208–13.CrossRefPubMed Kular A, Perry BI, Brown L, Gajwani R, Jasini R, Islam Z, Birchwood M, Singh SP. Stigma and access to care in first-episode psychosis. Early Interv Psychiatry. 2019;13(5):1208–13.CrossRefPubMed
10.
Zurück zum Zitat Salazar de Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, Soardo L, Cabras A, Fortea L, Catalan A, et al. Probability of transition to psychosis in individuals at clinical high risk: an updated Meta-analysis. JAMA Psychiatry. 2021;78(9):970–8.CrossRefPubMed Salazar de Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, Soardo L, Cabras A, Fortea L, Catalan A, et al. Probability of transition to psychosis in individuals at clinical high risk: an updated Meta-analysis. JAMA Psychiatry. 2021;78(9):970–8.CrossRefPubMed
11.
13.
Zurück zum Zitat McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018;17(2):133–42.CrossRefPubMedPubMedCentral McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018;17(2):133–42.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat McGorry PD. Truth and reality in early intervention. Aust N Z J Psychiatry. 2012;46(4):313–6.CrossRefPubMed McGorry PD. Truth and reality in early intervention. Aust N Z J Psychiatry. 2012;46(4):313–6.CrossRefPubMed
15.
Zurück zum Zitat Castle D. What, after all, is the truth: response to McGorry. Aust N Z J Psychiatry. 2012;46(7):685–7.CrossRefPubMed Castle D. What, after all, is the truth: response to McGorry. Aust N Z J Psychiatry. 2012;46(7):685–7.CrossRefPubMed
16.
Zurück zum Zitat Yung AR. Early intervention in psychosis: evidence, evidence gaps, criticism, and confusion. Aust N Z J Psychiatry. 2012;46(1):7–9.CrossRefPubMed Yung AR. Early intervention in psychosis: evidence, evidence gaps, criticism, and confusion. Aust N Z J Psychiatry. 2012;46(1):7–9.CrossRefPubMed
17.
Zurück zum Zitat McGorry PD, Mei C. Why do psychiatrists doubt the value of early intervention? The power of illusion. Australas Psychiatry. 2020;28(3):331–4.CrossRefPubMed McGorry PD, Mei C. Why do psychiatrists doubt the value of early intervention? The power of illusion. Australas Psychiatry. 2020;28(3):331–4.CrossRefPubMed
18.
Zurück zum Zitat Patel G. Reply to McGorry and Mei - ‘why do psychiatrists doubt the value of early intervention? The power of illusion’. Australas Psychiatry. 2020;28(5):598–9.CrossRefPubMed Patel G. Reply to McGorry and Mei - ‘why do psychiatrists doubt the value of early intervention? The power of illusion’. Australas Psychiatry. 2020;28(5):598–9.CrossRefPubMed
19.
Zurück zum Zitat Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–41.CrossRefPubMedPubMedCentral Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–41.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–306.CrossRefPubMed Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–306.CrossRefPubMed
Metadaten
Titel
First episode psychosis and beyond: much progress made but much more needed
verfasst von
Shuichi Suetani
Wei Wang
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Psychiatry / Ausgabe 1/2023
Elektronische ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-023-04639-6

Weitere Artikel der Ausgabe 1/2023

BMC Psychiatry 1/2023 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.